Hale Cory M, Seabury Robert W, Steele Jeffrey M, Darko William, Miller Christopher D
1 Department of Pharmacy, Upstate University Hospital, Syracuse, New York, NY, USA.
2 Department of Medicine, Upstate Medical University, Syracuse, New York, NY, USA.
J Pharm Pract. 2017 Jun;30(3):329-335. doi: 10.1177/0897190016642692. Epub 2016 Apr 12.
To determine whether there is an association between higher vancomycin trough concentrations and attainment of a calculated area under the concentration-time curve (AUC)/minimum inhibitory concentration (MIC) ≥400.
A retrospective analysis was conducted among vancomycin-treated adult patients with a positive methicillin-resistant Staphylococcus aureus (MRSA) culture. Attainment of a calculated AUC/MIC ≥400 was compared between patients with troughs in the reference range of 15 to 20 mg/L and those with troughs in the following ranges: <10, 10 to 14.9, and >20 mg/L. Nephrotoxicity was assessed as a secondary outcome based on corrected average vancomycin troughs over 10 days of treatment.
Overall, 226 patients were reviewed and 100 included. Relative to troughs ≥10, patients with vancomycin troughs <10 mg/L were 73% less likely to attain an AUC/MIC ≥400 (odds ratio [OR] 0.27, 95% confidence interval [CI]: 0.01-0.75). No difference was found in the attainment of an AUC/MIC ≥400 in patients with troughs of 10 to 14.9 mg/L and >20 mg/L when compared to patients with troughs of 15 to 20 mg/L. The mean corrected average vancomycin trough was higher in patients developing nephrotoxicity compared to those who did not (19.5 vs 14.5 mg/L, P < .001).
Achieving vancomycin serum trough concentrations of 15 to 20 mg/L did not result in an increased attainment of the AUC/MIC target relative to troughs of 10 to 14.9 mg/L but may increase nephrotoxicity risk.
确定较高的万古霉素谷浓度与达到计算的浓度-时间曲线下面积(AUC)/最低抑菌浓度(MIC)≥400之间是否存在关联。
对接受万古霉素治疗且耐甲氧西林金黄色葡萄球菌(MRSA)培养呈阳性的成年患者进行回顾性分析。比较谷浓度在15至20mg/L参考范围内的患者与谷浓度在以下范围的患者达到计算的AUC/MIC≥400的情况:<10mg/L、10至14.9mg/L和>20mg/L。基于治疗10天期间校正后的平均万古霉素谷浓度,将肾毒性作为次要结局进行评估。
总体而言,共审查了226例患者,其中100例纳入研究。与谷浓度≥10mg/L的患者相比,万古霉素谷浓度<10mg/L的患者达到AUC/MIC≥400的可能性低73%(比值比[OR]0.27,95%置信区间[CI]:0.01-0.75)。与谷浓度在15至20mg/L的患者相比,谷浓度在10至14.9mg/L和>20mg/L的患者在达到AUC/MIC≥400方面未发现差异。发生肾毒性的患者校正后的平均万古霉素谷浓度高于未发生肾毒性的患者(19.5 vs 14.5mg/L,P<.001)。
与谷浓度在10至14.9mg/L相比,将万古霉素血清谷浓度维持在15至20mg/L并不会增加达到AUC/MIC目标的比例,但可能会增加肾毒性风险。